Pre-made Lintuzumab benchmark antibody ( Whole mAb Radiolabelled, anti-CD33 therapeutic antibody, Anti-p67/SIGLEC3/SIGLEC-3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-314-1mg	1mg	Inquiry
GMP-Bios-ab-314-10mg	10mg	Inquiry
GMP-Bios-ab-314-100mg	100mg	Inquiry
GMP-Bios-ab-314-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody
INN Name	Lintuzumab
Target	CD33
Format	Whole mAb Radiolabelled
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	1996
Year Recommended	1997
Companies	PDL BioPharma;Seattle Genetics
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Acute myeloid leukaemia;Myelodysplastic syndromes
Development Tech	na